Friends - I like to do math, so here goes:

I went back and reviewed the press releases and data from various financial reports and here is what I have compiled:

Launch of Sensum+ - expected 2M/yr
Launch of Recalmax - expected 5M/yr
Zestra in US - expected 1.5M/yr
Zestra from South Korea - Guaranteed 2M/yr for 10yrs
UriVarx - expected 3M/yr

Then all BH products and Vesele actually did net revenues of ~900k back in Q2 and Vesele is their best seller. Conservatively, those 2 actually achieved 3.6M/yr

NOW - Let's just say we get 85% of the 4 "expected's" = 11.5M x 85% = 9.77M + 2 +3.6 = $15.37M


THIS DOES NOT INCLUDE:

Zestra India sales
Zestra Lebanon sales
Androferti sales
Eject Delay sales
Any 2nd half 2017 EU sales/agreements
Sales from new product launches like Xyralid

** Let's go extremely conservative and say ALL of the not includeds result in 1.5M in revs total for 2017...then we get a conservative $16.8M figure folks.

Obviously, FlutiCare approval brings in a full 12 months revenue of $12-14M more easy !